Novo Nordisk’s shares surged the most in a month following positive results from a real-world survey indicating that Ozempic, its flagship diabetes medication, outperformed Eli Lilly’s Trulicity among certain U.S. patients. The survey, which focused on the effectiveness and patient satisfaction of these treatments, suggested that Ozempic may have a competitive edge in real-world usage scenarios. This development has boosted investor confidence in Novo Nordisk amid ongoing competition in the diabetes market.
Ozempic has gained attention not only for its effectiveness in managing blood sugar levels but also for its role in weight loss, further enhancing its market appeal. The survey’s findings could influence prescribing patterns and patient preference, potentially impacting sales and market share for both companies. Eli Lilly’s Trulicity, a widely used GLP-1 receptor agonist, had previously been considered a leading treatment in this space.
Despite the positive survey results for Ozempic, analysts caution that real-world data may differ from clinical trial outcomes, and the overall market remains highly competitive. Both companies continue to innovate and expand their portfolios of diabetes medications, aiming to capture greater market share. The recent survey results highlight the importance of real-world evidence in shaping perceptions and decisions around diabetes treatments.